FDA approves Roche's Gazyva for primary membranous nephropathy, a first for the condition
The US regulator has cleared obinutuzumab for adults with primary membranous nephropathy at risk of progression, based on phase III MAJESTY data against tacrolimus.
Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Gazyva (obinutuzumab, marketed as Gazyvaro outside the US) for adults with primary membranous nephropathy who are at risk of disease progression. The indication is to induce remission of proteinuria. Roche describes it as the first therapy approved for this kidney disease.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Roche ↗
Article written by VigiEye from the official source (Roche). Claims are the company's own. AI-assisted; check the source before acting.